180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal Molecules
Yahoo! Finance
PALO ALTO, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that its pre-clinical study report on the effects of CBG (cannabigerol) derivatives on pain, inflammation and obesity was published in the journal Molecules. Working closely with cannabinoid medicinal
Continue Reading